These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 31658104)

  • 1. Ammonia Levels Do Not Guide Clinical Management of Patients With Hepatic Encephalopathy Caused by Cirrhosis.
    Haj M; Rockey DC
    Am J Gastroenterol; 2020 May; 115(5):723-728. PubMed ID: 31658104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Profile of hepatic encephalopathy in children with cirrhosis and response to lactulose.
    Sharma P; Sharma BC
    Saudi J Gastroenterol; 2011; 17(2):138-41. PubMed ID: 21372353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy.
    Agrawal A; Sharma BC; Sharma P; Sarin SK
    Am J Gastroenterol; 2012 Jul; 107(7):1043-50. PubMed ID: 22710579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lactulose vs polyethylene glycol 3350--electrolyte solution for treatment of overt hepatic encephalopathy: the HELP randomized clinical trial.
    Rahimi RS; Singal AG; Cuthbert JA; Rockey DC
    JAMA Intern Med; 2014 Nov; 174(11):1727-33. PubMed ID: 25243839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of rifaximin versus lactulose for reducing the recurrence of overt hepatic encephalopathy and hopitalizations in cirrhosis.
    Irimia R; Trifan A
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(4):1021-7. PubMed ID: 23700882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of nonresponse to lactulose in patients with cirrhosis and hepatic encephalopathy.
    Sharma P; Sharma BC; Sarin SK
    Eur J Gastroenterol Hepatol; 2010 May; 22(5):526-31. PubMed ID: 20009938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Rifaximin Plus Lactulose with the Lactulose Alone for the Treatment of Hepatic Encephalopathy.
    Ahire K; Sonawale A
    J Assoc Physicians India; 2017 Aug; 65(8):42-46. PubMed ID: 28799305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal treatment of hepatic encephalopathy.
    Waghray A; Waghray N; Kanna S; Mullen K
    Minerva Gastroenterol Dietol; 2014 Mar; 60(1):55-70. PubMed ID: 24632768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The response to combined therapy of hepatic encephalopathy in patients with hepatic cirrhosis].
    Maev IV; V'iuchnova ES; Lebedeva EG; Iakovenko EI; Dicheva DT
    Klin Med (Mosk); 2002; 80(5):42-5. PubMed ID: 12087887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lactulose is highly potential in prophylaxis of hepatic encephalopathy in patients with cirrhosis and upper gastrointestinal bleeding: results of a controlled randomized trial.
    Wen J; Liu Q; Song J; Tong M; Peng L; Liang H
    Digestion; 2013; 87(2):132-8. PubMed ID: 23485720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clearance and production of ammonia quantified in humans by constant ammonia infusion - the effects of cirrhosis and ammonia-targeting treatments.
    Eriksen PL; Djernes L; Vilstrup H; Ott P
    J Hepatol; 2023 Aug; 79(2):340-348. PubMed ID: 37061198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathophysiology, diagnosis, and management of hepatic encephalopathy.
    Sheasgreen C; Lu L; Patel A
    Inflammopharmacology; 2014 Dec; 22(6):319-26. PubMed ID: 25300964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of hepatic encephalopathy in the hospital.
    Leise MD; Poterucha JJ; Kamath PS; Kim WR
    Mayo Clin Proc; 2014 Feb; 89(2):241-53. PubMed ID: 24411831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum endotoxin, inflammatory mediators, and magnetic resonance spectroscopy before and after treatment in patients with minimal hepatic encephalopathy.
    Jain L; Sharma BC; Srivastava S; Puri SK; Sharma P; Sarin S
    J Gastroenterol Hepatol; 2013 Jul; 28(7):1187-93. PubMed ID: 23425082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy.
    Sharma BC; Sharma P; Lunia MK; Srivastava S; Goyal R; Sarin SK
    Am J Gastroenterol; 2013 Sep; 108(9):1458-63. PubMed ID: 23877348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hepatic encephalopathy and liver transplantation].
    Fehérvári I; Nemes B; Görög D; Gerlei Z; Kóbori L
    Magy Seb; 2012 Apr; 65(2):58-62. PubMed ID: 22512880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on management of patients with overt hepatic encephalopathy.
    Chacko KR; Sigal SH
    Hosp Pract (1995); 2013 Aug; 41(3):48-59. PubMed ID: 23948621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of nonresponse to lactulose for minimal hepatic encephalopathy in patients with cirrhosis.
    Sharma P; Sharma BC; Sarin SK
    Liver Int; 2009 Oct; 29(9):1365-71. PubMed ID: 19555401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary prophylaxis of overt hepatic encephalopathy in patients with cirrhosis: an open labeled randomized controlled trial of lactulose versus no lactulose.
    Sharma P; Sharma BC; Agrawal A; Sarin SK
    J Gastroenterol Hepatol; 2012 Aug; 27(8):1329-35. PubMed ID: 22606978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo.
    Sharma BC; Sharma P; Agrawal A; Sarin SK
    Gastroenterology; 2009 Sep; 137(3):885-91, 891.e1. PubMed ID: 19501587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.